Liankang Biotechnology Group (00690) announced interim results. Profit decreased by 59.0% year-on-year to approximately HK$31.2 million

According to the Zhitong Finance App, Liankang Biotechnology Group (00690) announced its 2026 interim results, with revenue of approximately HK$274 million, a year-on-year decrease of 11.75%; profit decreased by 59.0% year-on-year to approximately HK$31.2 million, with earnings per share of approximately HK0.52 cents.

According to the announcement, sales volume of major products continued to grow during the period, especially BOGOTAI® and Kineptide®. However, earnings were affected by one-time pricing adjustments during the period, mainly including repricing after successfully renewing the centralized procurement of Pinap®, strategically expanding the hospital admission and prescription base of Kineptide® through participation in the Guangdong Union Drug Centralized Procurement Project, and the impact of the increase in the VAT rate applicable to biological products from 3% to 13% on the net sales price.

The decline in profit mainly reflects short-term profit pressure during the Group's strategic transformation, including a decrease in absolute gross profit due to pricing adjustments for several core products and price effects related to VAT, as well as continued investment in commercialization, new product launches, pipeline development and international expansion.